Timothy Lee, Senior Vice President of Legal and Public Affairs, discusses the Federal Trade Commission's ill-advised push to ban noncompete clauses.

Timothy Lee, CFIF's Senior Vice President of Legal and Public Affairs, discusses the recent decision by the U.S. Court of Appeals for the Sixth Circuit to put a hold on the FCC's Title II Net Neutrality rules, and how history has proven that the consequences of Title II Net Neutrality are disastrous and immediate.

William J. Conti, an attorney from Washington, DC, discusses what would happen if President Biden stepped aside in the 2024 election, whether there is enough time for a new candidate to make a solid run, how the issue of President Biden's health has fractured the Democratic Party, and whether the 25th Amendment to the U.S. Constitution should come into play.

Timothy Lee, CFIF’s Senior Vice President of Legal and Public Affairs, discusses the current state of the U.S. economy and recent survey data on how Americans are doing financially under the Biden administration, and brings truth to some false statements being peddled by the media on issues related to the economy.

Phil Kerpen, President and Founder of American Commitment, discusses the Biden administration's electric vehicle mandate, what it may mean for Americans looking to purchase gas powered vehicles in the future, and what EV subsidies have really cost us.

Federal Communications Commission (FCC) Commissioner Brendan Carr discusses the FCC's upcoming vote on a rule that will subject the internet to crippling, utility-style regulatory powers under Title II of the Communications Act of 1934, the myths and facts surrounding "net neutrality," and how this massive expansion of government power over the internet is unnecessary at a time when Americans are experiencing lower prices, faster speeds, increased competition, and accelerated infrastructure build-outs.

Sally Pipes, President and CEO at the Pacific Research Institute, discusses how President Biden's drug price controls undermine his Cancer Moonshot initiative, and the ultimate impact price controls will have on patient lives, innovation, and research and development.